# A Study of Durvalumab (MEDI4736) in Esophageal Cancer

> **NCT02639065** · PHASE2 · COMPLETED · sponsor: **Shadia Jalal, MD** · enrollment: 39 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT02639065
- **Lead sponsor:** Shadia Jalal, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-27
- **Primary completion:** 2020-12-09
- **Final completion:** 2021-06-09
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2023-09-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639065, "A Study of Durvalumab (MEDI4736) in Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02639065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*